Journal
CHEMICAL SOCIETY REVIEWS
Volume 50, Issue 4, Pages 2839-2891Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0cs00011f
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [22035006]
- Zhejiang Provincial Natural Science Foundation of China [LD21B020001]
- Fundamental Research Funds for the Central Universities
Ask authors/readers for more resources
Nanotheranostics is the next generation of personalized medicine aiming to improve cancer patients' survival rate and quality of life. Supramolecular cancer nanotheranostics have advantages in early diagnosis and personalized therapy with promising potential in clinical applications.
Among the many challenges in medicine, the treatment and cure of cancer remains an outstanding goal given the complexity and diversity of the disease. Nanotheranostics, the integration of therapy and diagnosis in nanoformulations, is the next generation of personalized medicine to meet the challenges in precise cancer diagnosis, rational management and effective therapy, aiming to significantly increase the survival rate and improve the life quality of cancer patients. Different from most conventional platforms with unsatisfactory theranostic capabilities, supramolecular cancer nanotheranostics have unparalleled advantages in early-stage diagnosis and personal therapy, showing promising potential in clinical translations and applications. In this review, we summarize the progress of supramolecular cancer nanotheranostics and provide guidance for designing new targeted supramolecular theranostic agents. Based on extensive state-of-the-art research, our review will provide the existing and new researchers a foundation from which to advance supramolecular cancer nanotheranostics and promote translationally clinical applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available